Skip to main content
OpenTrials
Completed

NCT Number: NCT03613623

Acromegaly: Patient And Physician Perspectives

The purpose of the study is to assess the experiences of individuals with acromegaly who are receiving injections as part of their treatment regimen. Another objective of the study is to compare the patients' perception with their doctors' perceptions. The answers are important to help researchers and physicians understand what it is really like to take currently available treatments so that they can make efforts to improve patients' healthcare experiences, reduce treatment burden and, ultimately, improve patient's quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acromegaly Bone Diseases Bone Diseases, Endocrine Brain Diseases Central Nervous System Diseases Endocrine System Diseases Hyperpituitarism Hypothalamic Diseases Musculoskeletal Diseases Nervous System Diseases Pituitary Diseases

Age range

18 year–94 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tulane School of Public Health and Tropical Medicine

New Orleans, Louisiana, 70112, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >=18 years-old and <95 years-old
  • Patient self-reported acromegaly diagnosis which will be further confirmed by a knowledge screening based on current medications and doses
  • Currently on injectable Somatostatin analogues (SSA), Sandostatin® LAR or Somatuline® Depot, for >=12 months
  • Have not had a change in dosage of their acromegaly treatment at the time of or since their last office visit
  • Have seen their treating acromegaly physician within the past 12 +/-2 months NOTE: This timeframe allows two additional months for scheduling an appointment with their physician, since most patients should see their acromegaly physician at least once every 12 months
  • Ability to read and understand English
  • Live and receive acromegaly treatments in the US
  • Willing to provide signed informed consent

Exclusion criteria

  • Previous or current participant in Mycapssa® (octreotide capsules) trial
  • Use of Pegvisomant (Somavert®) monotherapy
  • Use of Pasireotide (Signifor®)

Treatment and study plan

Primary outcomes

  1. Assess patient experiences with acromegaly treatments through patient questionnaires.

    Time frame: The questionnaire should take no more than 60 minutes per subject.

    The primary objective of this study is to assess the experience of patients treated with SSA injections in the United States. Patients will be asked about previous and current acromegaly treatments they have taken from the time of diagnosis to the current day they are completing the survey.

  2. Assess patient satisfaction with acromegaly treatments.

    Time frame: The questionnaire should take no more than 60 minutes per subject.

    The primary objective of this study is to assess the treatment satisfaction of patients treated with SSA injections in the United States. Patients will be asked about previous and current acromegaly treatments they have taken from the time of diagnosis to the current day they are completing the survey.

  3. Assess patients with acromegaly health-related quality of life.

    Time frame: The questionnaire should take no more than 60 minutes per subject.

    The primary objective of this study is to assess the health-related quality of life for patients treated with SSA injections in the United States. Patients will be asked about their current quality of life and how acromegaly and acromegaly treatments may affect their quality of life from time of diagnosis to time of completing the survey.

Secondary outcomes

  1. Assess the concordance between patient's and physician's perceptions of acromegaly control (with/without biochemical lab results),

    Time frame: The questionnaire should take no more than 60 minutes per subject.

    The second objective of this study is to compare patients' perception with those of their physicians in terms of aspects such as acromegaly control, treatment satisfaction, and health-related quality of life (HRQoL).

  2. Assess the concordance between patient's and physician's perceptions of acromegaly treatment satisfaction.

    Time frame: The questionnaire should take no more than 60 minutes per subject.

    The second objective of this study is to compare patients' perception with those of their physicians in terms of aspects such as acromegaly treatment satisfaction.

  3. Assess the concordance between patient's and physician's perceptions of health-related quality of life.

    Time frame: The questionnaire should take no more than 60 minutes per subject.

    The second objective of this study is to compare patients' perception with those of their physicians in terms of aspects such as health-related quality of life (HRQoL).

Sponsors and collaborators

Lead sponsor

Tulane University

Other

Collaborators

  • Chiasma, Inc.

Registry information

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Aug 3, 2018
Registry last updated
Oct 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.